



Received on 11 August 2019; received in revised form, 11 September 2019; accepted, 25 September 2019; published 01 October 2019

SCREENING OF 4-([1,3,4]OXADIAZINO[6,5-b] INDOLE-3-YL)ANILINE DERIVATIVES FOR ANTI-BACTERIAL ACTIVITY BY *IN-SILICO* AND *IN-VITRO* METHODS

Meghna Bhamidipati and Konda Swathi *

Institute of Pharmaceutical Technology, Sri Padmavati Mahila Visvavidyalayam, Tirupathi - 517502, Andhra Pradesh, India.

Keywords:

Isatin, virtual screening,
Glucoseamine-6-phosphate synthase,
Dihydropteroate synthase

Correspondence to Author:

Dr. Konda Swathi

Ph.D., PDF. Associate Professor,
Institute of Pharmaceutical
Technology, Sri Padmavati Mahila
Visvavidyalayam, Tirupathi - 517502,
Andhra Pradesh, India.

E-mail: kswathi84@yahoo.co.in

ABSTRACT: Schiff bases of isatin are investigated overtime for their pharmaceutical properties and have been found to have various activities such as anti-viral, anti-bacterial, anti-inflammatory, analgesic, anti-HIV, anti-depressant, anti-convulsant, fungicidal, *etc.* Isatins are treated with hydrazine derivatives and cyclized by sulfuric acid. These compounds are alkylated by di alkyl aminoalkyl halides in specific catalysed conditions. In this study we focus on 4-([1,3,4]oxadiazino[6,5-b] indole-3-yl)aniline derivatives for anti-bacterial activity. Based on literature, glucoseamine-6-phosphate synthase (PDB ID: 2VF5) and dihydropteroate synthase (PDB ID: 1AJ0) enzymes are chosen as potential targets as showed activity for antibacterial and antifungal agents. The *in-silico* studies were carried out using Swiss ADME and Molinspiration *in-silico* tools and scoring of molecular docking *i.e.*, virtual screening was done by using AutoDock v.4.0. The *in-vitro* studies were carried out in the lab using cup-plate method and the zone of inhibition (in mm) was measured. The *in-silico* results were compared with that of *in-vitro* and a comparison was drawn. The activity of the compounds was found to have correlated.

INTRODUCTION: In the past two decades, antibiotic resistance has become an increasingly severe health problem. Bacterial infections caused by resistant strains are causing chaos in numerous hospitals around the world, especially in patients compromised by various factors like age, illness, and treated with immune-suppressant drugs. In this context, it is essential to increase the understanding of resistance mechanisms in order to develop drugs with potential activity against these pathogens. Hence, the need for the synthesis of newer classes of antibiotics with a novel mechanism of action is seen.

Therefore, the inhibition of microbial growth under standard conditions may be utilized for demonstrating the therapeutic efficacy of antibiotics. Any change in antibiotic molecule which may not be detected by chemical methods but will be revealed by the anti-microbial activity. Therefore, the microbiological assays are very useful for resolving doubts regarding the possible loss of potency of antibiotics¹⁻⁸.

Isatin or Tribulin is an indole derivative, the compound was first obtained by Erdmann⁹ and Laurent¹⁰ in 1841 as a product from the oxidation of indigo dye by nitric acid and chromic acids. The compound is found in many plants, such as *Isatistinctoria*, *Calanthe discolor* and *Couroupita guianensis*¹¹. The computational techniques in drug discovery have drastically reduced the time and cost involved in drug design and development it also reduced the failure rates to a large extent at critical stages of clinical trials.

<p>QUICK RESPONSE CODE</p>	<p style="text-align: center;">DOI: 10.13040/IJPSR.0975-8232.10(10).4799-05</p> <hr/> <p style="text-align: center;">This article can be accessed online on www.ijpsr.com</p>
<p>DOI link: http://dx.doi.org/10.13040/IJPSR.0975-8232.10(10).4799-05</p>	


The *in-silico* techniques have enhanced the understanding of molecular properties and the specific behavior or nature of drug-receptor interaction at molecular level. Molecular docking has become an important component of the drug discovery toolbox, and its relative low-cost implications and ease of use have stimulated ever-increasing popularity in the industry and amongst researchers. Glucosamine-6-phosphate synthase (GlcN-6-P) is a precursor of uridine diphospho-N-acetylglucosamine from which other amino sugar-containing molecules are derived. Because N-acetylglucosamine is an important constituent of the peptidoglycan layer of bacterial cell walls and fungal cell wall chitin, the enzyme is a potential target for antibacterial and antifungal agents¹².

The DHFR enzyme is a central player in the folate pathway that links divergent folate synthesis or acquisition mechanisms to the production of tetrahydrofolate (THF). An anti-folate target is dihydropteroate synthase (DHPS) is unique to prokaryotes. The drugs target the p-aminobenzoic acid (pABA) binding site of DHPS and interfere with folate biosynthesis and ultimately prevent bacterial replication^{13,14}.

In 2015, Sandra S. Konstatinovic reported and synthesized isatin -3-(4-hydroxy benzoyl hydrazone) and evaluated for anti-microbial activity¹⁵. Similar works on isatin derivatives were done, for example, Kalmeddin Haj Mohammad Ebrahim Tehrani in 2016 reported the synthesis and antimicrobial activity of Schiff's base of 5-substituted isatins¹⁶. In 2015, Sanjay Bari and Asmaa S. Salman synthesized and reported antimicrobial activity for benzothiazolo-isatins and 3-substituted indole derivatives respectively^{17,18}. In 2010 K. S. Nataraj reported synthesizing 21 new 2-((Benzalamino-4-hydroxy benzyl) (1, 3, 4)-oxadiazino[6,5,6])indole derivatives and screened them for antimicrobial activity¹⁹. Abdulsalam AM Alkhalidi, Mohamed A Abdelgawad, Bahaa GM Youssif *et al.*, reported synthesis, antimicrobial evaluation and docking studies (using glu-6-p in AutoDock v.4.0) of new pyrazolone derivatives III & IV for anti-microbial activity¹³.

Compound:

IUPAC Name: 4- ([1, 3, 4]oxadiazino[6, 5-b]indole-3-yl)aniline



Compound: 2a- R= H
 Compound: 2b- R= Cl
 Compound: 2c- R= CH₃
 Compound: 2d- R= NO₂
 Compound: 2e- R= Br

MATERIALS AND METHODS: The synthesised compounds were procured from the lab of IPT, SPMVV, Tirupati.

In-silico Study:

SwissADME- where we can predict:

i. Physicochemical Parameters: The parameters of the molecules which affect the nature of the compound. Ex: no: of rotatable bonds (n rot bonds), H-bond donors (H donor/acceptor) or acceptors, molecular weight, *etc.*

ii. Lipophilicity: From the various values of LogP, MlogP value is considered.

iii. Pharmacokinetic Parameters: The parameters like gastrointestinal absorption, blood-brain barrier penetrability, and P-glycoprotein substrate or inhibitor.

iv. Leadlikeness: A lead compound in drug discovery is a chemical compound that has pharmacological or biological activity likely to be therapeutically useful, but may nevertheless have a suboptimal structure that requires modification to fit better to the target.

v. Generate a boiled egg representation to show the absorption of the compound in GIT or the ability to penetrate BBB.

Molinspiration an online tool where the ADME properties of synthesized compounds can be determined. (<http://www.molinspiration.com/cgi-bin/properties>). It's used for the generation of the bioactivity scores of the compounds.

i. Bioactivity Score: Biological targets are the most common proteins such as enzymes, ion channels, and receptors. The biological target is

also referred to as a drug target. The bioactivity scores of the synthesized complexes were calculated for different parameters such as binding to G protein-coupled receptor (GPCR) ligand and nuclear receptor ligand, ion channel modulation, kinase inhibition, protease inhibition, and enzyme activity inhibition. The software predicts moderate biological activity for the synthesized complexes. It is known that for metal complexes, if the bioactivity score is more than 0.0, then the complex is active; if it is between -5.0 and 0.0 , then the complex is moderately active, and if the bioactivity score is less than -5.0 , then it is inactive.

Molecular Docking: The structures of ligand molecules were drawn using Chemdraw version 12.0. and were converted to a 3D conformation using ChemDraw Biochem 3D. Later their energy was minimized by using MMFF94 and MM2 energy fields. The structure of standard (streptomycin) was downloaded from ZINC database. Molecular docking studies were performed using AutoDock v.4.0. The 3D X-ray crystal structure of enzyme DHPS (Dihydropteroate synthase) (PDB ID: 1AJ0) and glucoseamine- 6- phosphatesynthase (glcN-6-P) (PDB ID: 2VF5) were imported from RCSB:PDB. The receptor grid with its ligand data was also obtained from the Protein Data Bank (PDB). The enzyme was prepared for docking studies.

It involves i) Removal of a ligand molecule and other heteroatoms from the enzyme active site. ii) Addition of polar hydrogens and charges to the structure with their standard geometry iii) The obtained model was used in predicting the ligand enzyme interaction at the active site. The prepared ligands and target molecules were docked, and the results are given in the table as best pose binding energy scores.




FIG. 1: PDB: 1AJ0




FIG. 2: PDB: 2VF5

Biological Evaluation of Anti-bacterial Activity:

The anti-bacterial activity was determined by the cup plate method (agar diffusion method) by measuring zone of inhibition at a concentration of $100 \mu\text{g/ml}$ against gram-positive (*Bacillus subtilis*, *S. aureus*) and gram-negative bacteria (*Escherichia coli*, *Pseudomonas vulgare*). Streptomycin was used as the standard drug at the concentration of $100 \mu\text{g/ml}$.

In-vitro Antibacterial Activity- Cup Plate

Method: ^{20, 21} Antimicrobial activity was performed by cup plate method by measuring zone of inhibition. Nutrient agar media for bacterial strain and sodium carboxymethyl cellulose (Sod.CMC) was used as solvent control. The stock culture was maintained. Bacterial inoculum was prepared by transferring a loop full of stock culture to the nutrient broth in conical flask. The flask was incubated at $34-37^\circ\text{C}$ for 24 h before experimentation. A volume of 25 ml of sterile hot agar medium was poured in each plate and allowed to harden on a level surface. The agar plates were inoculated with 24-h test inoculums by spreading uniformly with sterile cotton swabs. Bores were made on the medium using sterile borer. A volume of 0.1 ml of test solution was added to respective bores. Streptomycin at a concentration $100 \mu\text{g/ml}$ was taken as standard drug. A control of Sod. CMC was taken. The petri plates were kept in the refrigerator at 4°C for 15 min for diffusion to take place. Afterward they were incubated at 37°C for 24 h and zones of inhibition were observed and measured using a scale. The various antimicrobial activity results of synthesized compounds were shown in the Table.

RESULTS AND DISCUSSION: The compounds procured from the lab were tested using *in-silico* and *in-vitro* methods.

In-silico Studies: The *in-silico* analysis of the compounds was done using SwissADME and Molinspiration.

SwissADME: According to SwissADME studies, the compounds showed good pharmacokinetic

properties. They are BBB permeant (except 2d; R=NO₂) and were found to be P-glycoprotein substrates according to boiled egg representation as well *i.e.*, present in yolk region except for 2d (R=NO₂). The compounds obeyed Lipinski's rule with no violations and showed lead likeness.

TABLE 1: SwissADME STUDY DATA OF 4-([1,3,4]OXADIAZINO[6,5-B] INDOLE-3-YL)ANILINE DERIVATIVES

Compounds	Physicochemical Properties				Lipophilicity mlogP	Pharmacokinetics			Lipinski rule	Leadlikeness
	n-rot bonds	H- acceptor	H- donor	TPSA (°A)		GI	BBB	P-gp		
2a	1	4	1	77.83	2.11	High	Yes	Yes	Yes	Yes
2b	1	4	1	77.83	2.62	High	Yes	Yes	Yes	Yes
2c	1	4	1	77.83	2.36	High	Yes	Yes	Yes	Yes
2d	2	6	1	123.65	1.12	High	No	No	Yes	Yes
2e	1	4	1	77.83	2.75	High	Yes	Yes	Yes	Yes

Boiled Egg Representation: It shows us that this series of compounds have good BBB permeability

and indicates P-gp substrate nature (except 2d; R=NO₂).




FIG. 3: BOILED-EGG REPRESENTATION OF 4-([1,3,4] OXADIAZINO [6,5-B]INDOLE-3-YL)ANILINE DERIVATIVES

Molinspiration: In molinspiration, the compounds were found to be active as kinase inhibitors, ion channel inhibitors, and enzyme inhibitors,

moderately active as GPCR ligand, protease inhibitor and nuclear receptor ligands.

TABLE 2: MOLINSPIRATION STUDY DATA OF 4-([1,3,4]OXADIAZINO[6,5-B] INDOLE-3-YL)ANILINE DERIVATIVES

Compound	GPCRL	ICI	KI	NRL	PI	EI
2a	-0.15	0.02	0.19	-0.38	-0.27	0.07
2b	-0.12	0.01	0.2	-0.34	-0.25	0.04
2c	-0.16	-0.09	0.15	-0.35	-0.28	0.01
2d	-0.2	-0.03	0.1	-0.34	-0.28	-0.03
2e	-0.26	-0.12	0.16	-0.5	-0.39	-0.04

GPCRL- G-Protein Coupled receptor ligands, ICI- Ion Chanel Inhibitors, KI- Kinase Inhibitors, NRL- Nuclear Receptor Ligands, PI- Protease Inhibitors, EI- Enzyme Inhibitors

TABLE 3: BEST POSE BINDING ENERGY SCORE OF 4-([1,3,4]OXADIAZINO[6,5-B] INDOLE-3-YL)ANILINE WITH TARGETS 1AJ0 & 2VF5

Compound	1AJ0	2VF5
2a	-7.0	-7.4
2b	-6.9	-6.2
2c	-7.5	-6.1
2d	-7.4	-6.4
2e	-5.5	-6.5
Crystal Ligand	-4.3	-4.7
Streptomycin	-7.5	-7.5

Molecular Docking: The docking results of the compounds were recorded. All the compounds showed moderate to good docking scores. The best pose binding energy scores were in the range -8.25 to -9.42 for the protein 1AJ0 and -6.1 to -7.4 for the protein 2VF5.

The dock scores of most of the compounds were as good as the standard streptomycin.




FIG. 4: DOCKING OF LIGANDS ON 1AJ0




FIG. 5: DOCKING OF LIGANDS ON 2VF5

TABLE 4: ANTI-BACTERIAL ACTIVITY OF 4-([1,3,4]OXADIAZINO[6,5-B]INDOLE-3-YL)ANILINE DERIVATIVES USING STANDARD CUP-PLATE METHOD AND MEASURING ZONE OF INHIBITION (IN mm)

Sample	<i>E. coli</i>	<i>B. subtilis</i>	<i>S. aureus</i>	<i>P. vulgaris</i>
2a	36	29	28	30
2b	36	29	28	31
2c	15	17	20	19
2d	33	36	30	37
2e	34	32	29	31
Streptomycin	32	30	33	32

In-vitro Antibacterial Activity: The anti-bacterial study for compounds was done and the results show that some of the compounds showed moderate to good bacterial inhibition. The *in-vitro*

results of most of the compounds showed very good activity when compared to the standard.




FIG. 6: BAR GRAPH REPRESENTATION OF ZONE OF INHIBITION OF 4-([1, 3, 4]OXADIAZINO[6, 5-B]INDOLE-3-YL)ANILINE DERIVATIVES




FIG. 7: ANTI-BACTERIAL ACTIVITY OF STANDARD STREPTOMYCIN ON *E. COLI*




FIG. 8: ANTI-BACTERIAL ACTIVITY OF 2A ON *E. COLI*




FIG. 9: ANTI-BACTERIAL ACTIVITY OF 2B ON *B. SUBTILIS*




FIG. 10: ANTI-BACTERIAL ACTIVITY OF 2D ON *E. COLI*



FIG. 11: ANTI-BACTERIAL ACTIVITY OF 2D ON *P. VULGARIS*



FIG. 12: ANTI-BACTERIAL ACTIVITY OF 2E ON *E. COLI*




FIG. 13: ANTI-BACTERIAL ACTIVITY OF 2C ON *P. VULGARIS*

CONCLUSION: The compounds series-2(4-([1,3,4]oxadiazino[6,5-b] indole-3-yl)aniline derivatives), according to SwissADME study, the compounds showed good pharmacokinetic properties. The boiled-egg feature showed that they are BBB permeant *i.e.*, present in yolk region and were found to be P-glycoprotein substrates (except 2d; R=NO₂). The compounds obeyed Lipinski's rule with no violations and showed lead likeness. According to the Molinspiration study, the compounds were found to be active as kinase inhibitors, ion channel inhibitors, and enzyme inhibitors, moderately active as GPCR ligand, protease inhibitor, and nuclear receptor ligands. The molecular docking study in two targets showed good to moderated binding scores on AutoDock v.4.0. They also showed good to moderate activity in *in-vitro* testing of these compounds against gram-positive (*Bacillus subtilis*, *Staphylococcus aureus*) and gram-negative bacteria (*Escherichia coli*, *Pseudomonas vulgare*) for anti-bacterial activity using cup plate method.

From the above observations, we can conclude by saying that these compounds showed lead likeness and showed good anti-bacterial activity *in-silico* as well as *in-vitro* studies. Therefore, *in-silico* and *in-vivo* studies have correlated. These moieties can be taken further in research for newer antibiotics.

ACKNOWLEDGEMENT: This work was supported by the Institute of Pharmaceutical Technology, Sri Padmavathi Mahila Visvavidyalayam, Tirupati.

CONFLICT OF INTEREST: Conflict of interest declared none by the authors.

REFERENCES:

1. Sahoo S, Mahendrakumar CB and Setty C: Synthesis, anti-inflammatory and antibacterial activities of some substituted isatin and isatin fused with 3 substituted 4-amino-5-mercapto 1, 2, 4-triazoles. *International Journal of Chemical Sciences* 2015; 13: 613-24.
2. Ibrahim MM, Elsaman T and Al-Nour MY: Synthesis, anti-inflammatory activity, and *in-silico* study of novel diclofenac and isatin conjugates. *International Journal of Medicinal Chemistry* 2018; 1-11.

3. Swathi K, Manasa C and Sarangapani M: Development of novel indole molecules for the screening of anti-inflammatory activity. In: Vlamos P. (eds) *GeNeDis 2016. Advances in Experimental Medicine and Biol* 2016; 988.
4. Blessi P, Pogula M, Suresh S, Thirupathi K and Sammaiah G: Synthesis and characterization of new indole derivatives for analgesic activity. *International Journal of Pharmacy and Pharmaceutical Sciences* 2012; 4: 231-33.
5. Sriram D and Yogeeswari P and Meena K: Synthesis, anti-HIV and antitubercular activities of isatin derivatives. *Die Pharmazie* 2006; 61: 274-7.
6. Deweshri K, Menghani S and Khedekar P: Synthesis, characterization, antidepressant activity and docking studies of some novel indole bearing azetidione derivatives. *Ind J of Phar Edu and Res* 2018; 52: 110-21.
7. Prakash CR, Raja S and Saravanan G: Synthesis, characterization and anticonvulsant activity of novel Schiff base of isatin derivatives. *International Journal of Pharmacy and Pharmaceutical Sciences* 2010; 2: 177-81.
8. AA Patel Chapter-IV: *Antimicrobial Activity* 2(1): 69-71.
9. Erdmann OL: *Untersuchungentiber den Indigo*. *J Prakt Chem* 1841; 24: 1-18.
10. Laurent A: *Untersuchungenüber den Indigo*. *J Prakt Chem* 1842; 25: 430-74.
11. <https://en.wikipedia.org/wiki/Isatin>
12. Bearn SL and Blouin C: Inhibition of *Escherichia coli* glucosamine-6-phosphate synthase by reactive intermediate analogues. *J of Biol Chem* 2000; 275(1): 135-40.
13. Alkhalidi AAM, Abdelgawad MA and Youssif BGM: Synthesis, antimicrobial evaluation and docking studies of new pyrazolone derivatives. *Tropical Journal of Pharmaceutical Research* 2018; 17(11): 2235-41.
14. Ezeokonkwo MA, Ogbonna ON, Okafor SN, Godwin-Nwakwasi EU, Ibeanu FN and Okoro UC: Angular phenoaxine ethers as potent multi-microbial targets inhibitors: Design, synthesis, and molecular docking studies. *Frontiers in Chemistry* 2017; 5: 1-15.
15. Sukdolak S, Solujić S, Vuković N and Milošević T: The synthesis and antimicrobial activity of γ -butyrolactone derivatives. *Turkish Journal of Chem* 2008; 32(5): 615-21.
16. Kamaledin T, Hassan M, Kobarfard F and Shohreh M: Synthesis and antibacterial activity of Schiff bases of 5-substituted isatins. *Chinese Chemical Letters* 2015; 27.
17. Bari S, Manda S and Ugale V, Jupally V and Venkatesham A: Rational design and synthesis of benzothiazolo-isatins for antimicrobial and cytotoxic activities. *Indian Journal of Chemistry Section B* 2015; 54: 418-29.
18. Salman A, Mahmoud N, Abdelaziem A, Mohamed M and Elsis D: Synthesis, reactions and antimicrobial activity of some new 3-substituted indole derivatives. *International Journal of Organic Chemistry* 2015; 5: 81-99.
19. Nataraj KS, Rao JV and Jayaveera KN: Synthesis and antimicrobial activity of new indole derivatives. *Int J Chem Sci* 2010; 8(1): 609-16.
20. Aniyery R, Gupta A and Singh P: *In-vitro* and in silico antimicrobial study of stannane of pyridoxal 5-phosphate. *Int J of Pharmacy and Pharm Sci* 2016; 9: 145-53.
21. Vijesh AM and Isloor AM: Molecular docking studies of some new imidazole derivatives for antimicrobial properties. *Arabian J of Chemistry* 2013; 6(2): 197-04.

How to cite this article:

Bhamidipati M and Swathi K: Screening of 4-([1,3,4]oxadiazino[6,5-b] indole-3-yl)aniline derivatives for anti-bacterial activity by *in-silico* and *in-vitro* methods. *Int J Pharm Sci & Res* 2019; 10(10): 4799-05. doi: 10.13040/IJPSR.0975-8232.10(10).4799-05.